Compare PGC & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGC | SLS |
|---|---|---|
| Founded | 1921 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 836.7M | 924.5M |
| IPO Year | 1997 | 2007 |
| Metric | PGC | SLS |
|---|---|---|
| Price | $46.54 | $11.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $40.50 | $10.00 |
| AVG Volume (30 Days) | 220.8K | ★ 10.5M |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.48% | N/A |
| EPS Growth | 13.51 | ★ 50.00 |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $282,995,000.00 | N/A |
| Revenue This Year | $32.39 | N/A |
| Revenue Next Year | $12.64 | $110.98 |
| P/E Ratio | $57.10 | ★ N/A |
| Revenue Growth | ★ 24.05 | N/A |
| 52 Week Low | $24.45 | $1.39 |
| 52 Week High | $49.14 | $15.88 |
| Indicator | PGC | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 53.61 | 47.46 |
| Support Level | $44.79 | $3.91 |
| Resistance Level | $47.18 | $15.88 |
| Average True Range (ATR) | 1.48 | 1.33 |
| MACD | -0.19 | -0.38 |
| Stochastic Oscillator | 63.90 | 1.33 |
Peapack Gladstone Financial Corp is a bank holding company. Through its subsidiaries, the company offers various wealth management, investment banking, and commercial and personal banking solutions to its clients. The company has two reportable segments: Banking, which generates the maximum revenue, and Wealth Management. The Banking segment includes commercial, commercial real estate, multifamily, residential, and consumer lending activities; treasury management services; escrow management; deposit generation; operation of ATMs; telephone and internet banking services; credit card services, etc. The Wealth Management segment offers investment management services for individuals and institutions; personal trust services; and other financial planning and advisory services.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.